Horizon Life Sciences Group, the global life sciences engineering and manufacturing solutions provider, has officially launched its new subsidiary company, SeriCode™ – the strategic partner for serialisation implementation in the pharmaceutical industry.
SeriCode’s mission is to be a champion for patient safety by leading the way for the eradication of counterfeit drugs. It is a strategic partner for pharmaceutical manufacturing companies who are undertaking serialisation implementation, a process which is being driven globally and in Europe by the recently published EU Falsified Medicine Directive which will be mandatory by 9 February 2019. The company serves the customers with two divisions, Engineering Services, which provides project managed in-house expertise to clients, and an Outsourced Solutions, where serialisation is conducted in SeriCode’s GMP compliant facility in Mayo.
Thomas Merle, CEO, SeriCode™ said: “Serialisation impacts the whole supply chain and may be one of the biggest operational challenges that companies in the life sciences industry have ever faced. SeriCode™ is the key provider of solutions in the pharmaceutical sector. With our skilled engineers and targeted expertise, the company is working towards eliminating counterfeit drugs for patients’ safety. Through our parent company, Horizon Life Sciences Group, we are dedicated to developing products and solutions to aid the health, safety and well-being of the global community, in collaboration with our clients.”
Horizon Life Sciences Group subsidiaries also include Team Horizon, the global life sciences engineering solutions provider with an expert focus on the pharma and biopharma manufacturing processes.